New medical approaches in advanced ovarian cancer

Giacomo Corrado, Eleonora Palluzzi, Carolina Bottoni, Antonella Pietragalla, Vanda Salutari, Viola Ghizzoni, Mariagrazia Distefano, Giovanni Scambia, Gabriella Ferrandina

Research output: Contribution to journalReview articlepeer-review


Ovarian cancer is the fifth leading cause of cancer death among women and the most lethal gynecologic malignancy. Most women with advanced epithelial ovarian cancer will experience many episodes of recurrent disease with progressively shorter disease-free intervals. For women whose disease continues to respond to platinum-based drugs, the disease can often be controlled for 5 years or more. Enormous progress has been made in the management of this disease, and new targeted treatments such as antiangiogenic drugs, poly(adenosine diphosphate-ribose) polymerase inhibitors, and immune checkpoint inhibitors offer potential for improved survival. A variety of combination strategies are being evaluated to leverage these agents. The objective of this review is to summarize results from clinical trials that tested cytotoxic drugs and target strategies for the treatment of ovarian cancer with particular attention to Phase III and ongoing trials.

Original languageEnglish
Pages (from-to)367-384
Number of pages18
JournalMinerva Medica
Issue number4
Publication statusPublished - Aug 2019


  • Carcinoma, Ovarian Epithelial/pathology
  • Female
  • Humans
  • Neoplasm Staging
  • Ovarian Neoplasms/pathology


Dive into the research topics of 'New medical approaches in advanced ovarian cancer'. Together they form a unique fingerprint.

Cite this